תאריך רישום: September 2, 1993

מסלול הגשה: מולקולה חדשה

יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND

בעל רישום: FERRING PHARMACEUTICALS LTD

A07EC02 :ATC Code

4.1 Therapeutic indications Treatment of mild to moderate ulcerative colitis and Crohn’s disease.

תאריך רישום: November 30, 1982

מסלול הגשה: מולקולה חדשה

יצרן: MADAUS GMBH, GERMANY

בעל רישום: MEGAPHARM LTD

A12BA02 :ATC Code

4.1 Therapeutic indications To dissolve uric acid stones in the urinary tract. Prevention of further stone formation. Note: Product administration should be part of a general concept of metaphylaxis (i.e. diet, increased fluid uptake etc.). Mechanism of Action Uric acid is sparingly soluble or completely insoluble in solutions of greater acidity (i.e. pH below 6), and under these conditions, it forms crystals and in unfavourable circumstances may grow into stones. Uralyt-U action is based on the fact that it can stabilize the pH of urine within the correct pH range of 6.2 to 6.8. Thus Uralyt-U improves the solubility of uric acid and prevents the formation of uric acid crystals (stones) and also re-dissolves any crystals (stones) that are already present. Uralyt-U is free from carbohydrates and can therefore safely be taken by diabetics.

תאריך רישום: April 24, 1983

מסלול הגשה: מולקולה חדשה

יצרן: ALMIRALL HERMAL GMBH, GERMANY

בעל רישום: NEOPHARM LTD

D10AF02 :ATC Code

4.1 Therapeutic indications All forms of acne, in particular inflammatory forms with papules and pustules.

תאריך רישום: January 20, 1999

מסלול הגשה: מולקולה חדשה

יצרן: JANSSEN PHARMACEUTICA N.V, BELGIUM

בעל רישום: J-C HEALTH CARE LTD

N05AX08 :ATC Code

Therapeutic Indications RISPERDAL is indicated for the management of schizophrenia, and the manifestations of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic in-patients. RISPERDAL is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. RISPERDAL is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated- aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. RISPERDAL is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors.

תאריך רישום: September 3, 2003

מסלול הגשה: מולקולה חדשה

יצרן: EXCELLA GMBH & CO. KG, GERMANY

בעל רישום: PADAGIS ISRAEL AGENCIES LTD, ISRAEL

L01AB01 :ATC Code

4.1 Therapeutic Indications For the palliative treatment of chronic granulocytic leukaemia (also called chronic myeloid leukaemia).

תאריך רישום: March 14, 1999

מסלול הגשה: מולקולה חדשה

יצרן: SANOFI WINTHROP INDUSTRIE, FRANCE

בעל רישום: PHARMASHALOM

R06AX25 :ATC Code

4.1 Therapeutic indications Mizolastine is a long acting H1- antihistamine indicated for the symptomatic treatment of seasonal allergic rhinoconjunctivitis (hay fever), perennial allergic rhinoconjunctivitis and urticaria.